HGF/SF Mab therapies under different phases of ongoing clinical trials for various cancers include Rilotumumab from Amgen, Ficlatuzumab from AVEO pharmaceuticals and HuL2G7 from Millennium pharmaceuticals (www.vai.org/metclinicaltrials; [100]). The gene discussed is HGF; the disease is cancer.